Mitochondrial metabolism as a target for acute myeloid leukemia treatment
Autor: | Jingqi Pei, Natalia V. Kirienko, S. B. Panina |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Drug
Mitochondrial DNA Mitochondrial abnormalities/alterations media_common.quotation_subject medicine.medical_treatment Oxidative phosphorylation Review Mitochondrion medicine Acute myeloid leukemia (AML) RC254-282 media_common Chemotherapy business.industry Drug combinations Myeloid leukemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens Mitochondria Psychiatry and Mental health Haematopoiesis Synergy Mitochondrial metabolism Mitocans Cancer research Stem cell business Leukemia stem cells |
Zdroj: | Cancer & Metabolism, Vol 9, Iss 1, Pp 1-25 (2021) Cancer & Metabolism |
ISSN: | 2049-3002 |
Popis: | Acute myeloid leukemias (AML) are a group of aggressive hematologic malignancies resulting from acquired genetic mutations in hematopoietic stem cells that affect patients of all ages. Despite decades of research, standard chemotherapy still remains ineffective for some AML subtypes and is often inappropriate for older patients or those with comorbidities. Recently, a number of studies have identified unique mitochondrial alterations that lead to metabolic vulnerabilities in AML cells that may present viable treatment targets. These include mtDNA, dependency on oxidative phosphorylation, mitochondrial metabolism, and pro-survival signaling, as well as reactive oxygen species generation and mitochondrial dynamics. Moreover, some mitochondria-targeting chemotherapeutics and their combinations with other compounds have been FDA-approved for AML treatment. Here, we review recent studies that illuminate the effects of drugs and synergistic drug combinations that target diverse biomolecules and metabolic pathways related to mitochondria and their promise in experimental studies, clinical trials, and existing chemotherapeutic regimens. |
Databáze: | OpenAIRE |
Externí odkaz: |